A bill aimed at limiting US companies’ use of Chinese contract manufacturers suffered a setback when senators omitted it from a critical defense budget bill. The BIOSECURE Act, which targets WuXi AppTec and WuXi Biologics, would have restricted U.S. pharmaceutical and biotechnology firms from using services from these key Chinese companies funded by the federal government. Industry experts warn that exclusion would significantly increase costs for contract manufacturing services. Despite bipartisan support, lawmakers chose not to include it in the must-pass defense bill.
Source: https://www.statnews.com/2024/12/08/biosecure-anti-china-bill-aimed-at-wuxi-drug-manufacturers-dealt-blow